Parth Patel, MD
MOHS-Micrographic Surgery · Bridgewater, NJNPI 1023547601
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 227 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,028, more than ten times the $15 reported in 2022.
Across 227 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$665
- Lilly USA, LLC$479
- UCB, Inc.$414
- AbbVie$394
- Organogenesis Inc.$294
- Abbott$234
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,268100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 46 | $665 |
| Lilly USA, LLC | 21 | $479 |
| UCB, Inc. | 30 | $414 |
| AbbVie | 26 | $394 |
| Organogenesis Inc. | 8 | $294 |
| Abbott | 2 | $234 |
| Amgen | 6 | $214 |
| Sanofi | 8 | $160 |
| Sun Pharmaceutical Industries Inc. | 8 | $138 |
| Regeneron Healthcare Solutions, Inc. | 8 | $136 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $119 |
| Galderma Laboratories, L.p. | 7 | $110 |
| Johnson & Johnson | 6 | $103 |
| Novartis | 5 | $81 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Biofrontera Inc. | 4 | $68 |
| Arcutis Biotherapeutics, Inc. | 4 | $62 |
| Medtronic | 2 | $59 |
| Organon | 4 | $58 |
| LEO Pharma Inc. | 3 | $52 |
| Kerecis Limited | 2 | $52 |
| Boehringer Ingelheim | 3 | $49 |
| Pfizer | 2 | $44 |
| Mayne Pharma Commercial LLC | 2 | $43 |
| Medshape, Inc. | 1 | $27 |
| Averitas Pharma Inc. | 1 | $22 |
| Krystal Biotech Inc | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Convatec Inc. | 1 | $18 |
| Journey Medical Corporation | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$140
- Otezla$125
- SIMPLIMAX$120
How this compares
$4,268 in reported general payments places this provider in the 75th percentile of 30 mohs-micrographic surgery providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 26 | $103,165 |
| OpzeluraRuxolitinib Phosphate | 13 | $37,080 |
| Tacrolimus | 42 | $7,610 |
| Clobetasol Propionate | 79 | $3,520 |
| Calcipotriene | 14 | $2,812 |
| Ketoconazole | 83 | $1,989 |
| Azelaic Acid | 16 | $1,357 |
| Triamcinolone Acetonide | 136 | $1,251 |
| Betamethasone Dipropionate | 25 | $1,076 |
| Metronidazole | 13 | $686 |
| CiclopiroxCiclopirox Olamine | 16 | $566 |
| Hydrocortisone | 64 | $401 |
| Doxycycline Monohydrate | 27 | $354 |
| Timolol Maleate | 11 | $263 |
| ValacyclovirValacyclovir Hcl | 15 | $250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $665 | $37,08013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 30 mohs-micrographic surgery providers in New Jersey.
Other mohs-micrographic surgery in Bridgewater
- David GoldbergHackensack$820K
- Marc GlashoferWest Orange$175K
- Kehua LiSewell$22K
- Steven WangBasking Ridge$11K
- John VinePrinceton$8K
- Lian Jie LiPhillipsburg$7K
- David NajarianRandolph$5K
- Shreya PatelWest Orange$3K
- Jeffrey WhitworthWoodland Park$3K
- Otter AspenRockaway$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.